Skip to content

Structure-based discovery of conformationally selective inhibitors of the serotonin transporter.

Isha Singh, Anubha Seth, Christian B. Billesbølle, Joao M Braz, Ramona M. Rodriguiz, Kasturi Roy, Bethlehem Bekele, Veronica Craik, Xi-Ping Huang, Danila Boytsov, Vladimir M Pogorelov, Parnian Lak, Henry O'Donnell, Walter Sandtner, John J. Irwin, Bryan L. Roth, Allan I. Basbaum, William C. Wetsel, Aashish Manglik, Brian K. Shoichet, Gary Rudnick

Cell May 11, 2023 DOI: 10.1016/j.cell.2023.04.010 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Computational docking and experimental validation Peer reviewed
Population Mice
Topics Addiction Depression Serotonin
Keywords Docking Functional selectivity Serotonin transporter Potent compounds Promising path Screened molecules Pharmacology anti-depressant effects Anti-anxiety effects Reversing morphine withdrawal Improved safety Neuroscience anti-depressant Screened ultra-large libraries
Citations 97
Key findings Two potent, low-nanomolar SERT inhibitors that stabilize an outward-closed state showed anxiolytic- and anti-depressant-like activity up to 200-fold better than fluoxetine in mice, and one reversed morphine withdrawal effects.

Abstract

The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has unusual anti-depressant and substance-withdrawal effects, and stabilizes the inward-open conformation. Unfortunately, ibogaine's promiscuity and cardiotoxicity limit the understanding of inward-open state ligands. We docked over 200 million small molecules against the inward-open state of the SERT. Thirty-six top-ranking compounds were synthesized, and thirteen inhibited; further structure-based optimization led to the selection of two potent (low nanomolar) inhibitors. These stabilized an outward-closed state of the SERT with little activity against common off-targets. A cryo-EM structure of one of these bound to the SERT confirmed the predicted geometry. In mouse behavioral assays, both compounds had anxiolytic- and anti-depressant-like activity, with potencies up to 200-fold better than fluoxetine (Prozac), and one substantially reversed morphine withdrawal effects.

Explore topics